Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infliximab Clear all
Recruiting No phase listed Observational

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

NCT04331639
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 4 Interventional

Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

NCT00574470
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
daclizumab, infliximab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional

Infliximab to Treat Children With Juvenile Rheumatoid Arthritis

NCT00029042
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2008 · Synced Oct 16, 2026, 10:08 PM EDT
Completed No phase listed Observational

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

NCT01698515
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 16, 2026, 10:08 PM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT02694770
View directory record Official record
Conditions
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Interventions
Neihulizumab Treatment, Conventional Treatment
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Not applicable Interventional Results available

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

NCT01438151
View directory record Official record
Conditions
Crohn's Disease
Interventions
Remicade
Drug
Lead sponsor
Shradha Agarwal
Other
Eligibility
7 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Oct 16, 2026, 10:08 PM EDT
Completed No phase listed Observational Results available

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

NCT05375942
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Collegeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional Results available

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

NCT01485055
View directory record Official record
Conditions
Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
Interventions
Infliximab and Basiliximab
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Months to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 16, 2026, 10:08 PM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

NCT00959725
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

Precise Infliximab Exposure and Pharmacodynamic Control

NCT05660746
View directory record Official record
Conditions
Crohn Disease
Interventions
RoadMAB, Infliximab
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

NCT02937701
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 710, Infliximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Not applicable Interventional

Transcutaneous VNS to Treat Pediatric IBD

NCT03863704
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 16, 2026, 10:08 PM EDT
Completed No phase listed Observational Results available

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

NCT02438410
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00105300
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
46
States / cities
Huntsville, Alabama • Roseville, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

NCT03446976
View directory record Official record
Conditions
Health, Subjective
Interventions
CT-P13 SC Auto-injector, CT-P13 SC Pre-filled Syringe
Biological
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
strength training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

NCT01844804
View directory record Official record
Conditions
Healthy
Interventions
PF-06438179, Remicade
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Not applicable Interventional Results available

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

NCT02413047
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions
Azathioprine, 6 mercaptopurine, Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 16, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 16, 2026, 10:08 PM EDT